The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency
Objective: In a large group of patients with primary immunodeficiency (PID), immunoglobulin replacement therapy is critical for infection control. There are two main methods of immunoglobulin replacement intravenous (IVIG) and subcutaneous (SCIG). The aim of this study was to determine the efficacy...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aydın Pediatric Society
2023-06-01
|
| Series: | Trends in Pediatrics |
| Subjects: | |
| Online Access: | https://trendspediatrics.com/article/view/89 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849718273037303808 |
|---|---|
| author | Selime Özen Bölük Nesrin Gülez Canan Karkıner Özgen Soyöz Figen Çelebi Çelik Mehmet Şirin Kaya Idil Akay Hacı Ilke Taşkırdı Ömer Akçal Ferah Genel |
| author_facet | Selime Özen Bölük Nesrin Gülez Canan Karkıner Özgen Soyöz Figen Çelebi Çelik Mehmet Şirin Kaya Idil Akay Hacı Ilke Taşkırdı Ömer Akçal Ferah Genel |
| author_sort | Selime Özen Bölük |
| collection | DOAJ |
| description |
Objective: In a large group of patients with primary immunodeficiency (PID), immunoglobulin replacement therapy is critical for infection control. There are two main methods of immunoglobulin replacement intravenous (IVIG) and subcutaneous (SCIG). The aim of this study was to determine the efficacy of SCIG by comparing IgG levels and frequency of infections obtained during SCIG replacements in patients with PID with those obtained during IVIG administration.
Method: Immunoglobulin levels of 28 patients who were followed up in our clinic with a diagnosis of PID and who started IVIG replacement and switched to SCIG replacement after follow-up, were evaluated retrospectively. Serum IgG levels and frequency of infections before starting immunoglobulin treatment, the previous year of IVIG before starting SCIG replacement, and during the first six months, second six months, and second year of SCIG replacement were compared.
Results: The mean age of all the patients that received SCIG was 10.5 years (min 15 months, max 23 years) and eleven of the patients were female. The mean serum IgG level of the patients before starting immunoglobulin replacement was 701±383 mg/dl, and for the final year they received IVIG replacement before switching to SCIG replacement it was calculated to be 900±342 mg/dl. The mean value was found to be 1082±312 mg/dl in the first six months after the initiation of SCIG, 1102±287 mg/dl in the second six months, and 1145±311 mg/dl in the second year. Serum IgG levels of the patients were significantly higher during IVIG and SCIG replacement than before treatment (p<0.05). Serum IgG levels during the first six months, second six months, and second year of SCIG treatment were significantly higher than levels during IVIG treatment (p=0.000, p=0.003, and p=0.002, respectively).
Conclusion: Compared to IVIG replacement, significantly higher and more stable serum IgG levels can be obtained with SCIG replacement. This is expected to ensure improved outcomes in the management of infections in PID patients.
|
| format | Article |
| id | doaj-art-08ac4bf1a1c14648b8a7cb6ef9fa0733 |
| institution | DOAJ |
| issn | 2792-0429 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Aydın Pediatric Society |
| record_format | Article |
| series | Trends in Pediatrics |
| spelling | doaj-art-08ac4bf1a1c14648b8a7cb6ef9fa07332025-08-20T03:12:24ZengAydın Pediatric SocietyTrends in Pediatrics2792-04292023-06-014210.59213/TP.2023.32548The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiencySelime Özen Bölük0https://orcid.org/0000-0002-7156-7480Nesrin Gülez1https://orcid.org/0000-0002-3343-6949Canan Karkıner2https://orcid.org/0000-0001-6662-8288Özgen Soyöz3https://orcid.org/0000-0002-4540-352XFigen Çelebi Çelik4https://orcid.org/0000-0002-1100-4117Mehmet Şirin Kaya5https://orcid.org/0000-0001-9416-9058Idil Akay Hacı6https://orcid.org/0000-0002-0965-0726Ilke Taşkırdı7https://orcid.org/0000-0001-9326-2541Ömer Akçal8https://orcid.org/0000-0002-3046-7133Ferah Genel9https://orcid.org/0000-0002-9976-067XAydin Gynecology and Pediatric Hospital, Department of Pediatrics, Division of Allergy and Immunology, Aydın, TürkiyeUniversity of Health Sciences İzmir Dr. Behcet Uz Children’s Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, TürkiyeUniversity of Health Sciences İzmir Dr. Behcet Uz Children’s Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, TürkiyeUniversity of Health Sciences İzmir Dr. Behcet Uz Children’s Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, TürkiyeUniversity of Health Sciences İzmir Dr. Behcet Uz Children’s Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, TürkiyeUniversity of Health Sciences İzmir Dr. Behcet Uz Children’s Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, TürkiyeUniversity of Health Sciences İzmir Dr. Behcet Uz Children’s Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, TürkiyeTepecik Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, TürkiyeBiruni University, Faculty of Medicine, Department of Pediatrics, Division of Allergy and Immunology, İstanbul, TürkiyeUniversity of Health Sciences İzmir Dr. Behcet Uz Children’s Education and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, İzmir, Türkiye Objective: In a large group of patients with primary immunodeficiency (PID), immunoglobulin replacement therapy is critical for infection control. There are two main methods of immunoglobulin replacement intravenous (IVIG) and subcutaneous (SCIG). The aim of this study was to determine the efficacy of SCIG by comparing IgG levels and frequency of infections obtained during SCIG replacements in patients with PID with those obtained during IVIG administration. Method: Immunoglobulin levels of 28 patients who were followed up in our clinic with a diagnosis of PID and who started IVIG replacement and switched to SCIG replacement after follow-up, were evaluated retrospectively. Serum IgG levels and frequency of infections before starting immunoglobulin treatment, the previous year of IVIG before starting SCIG replacement, and during the first six months, second six months, and second year of SCIG replacement were compared. Results: The mean age of all the patients that received SCIG was 10.5 years (min 15 months, max 23 years) and eleven of the patients were female. The mean serum IgG level of the patients before starting immunoglobulin replacement was 701±383 mg/dl, and for the final year they received IVIG replacement before switching to SCIG replacement it was calculated to be 900±342 mg/dl. The mean value was found to be 1082±312 mg/dl in the first six months after the initiation of SCIG, 1102±287 mg/dl in the second six months, and 1145±311 mg/dl in the second year. Serum IgG levels of the patients were significantly higher during IVIG and SCIG replacement than before treatment (p<0.05). Serum IgG levels during the first six months, second six months, and second year of SCIG treatment were significantly higher than levels during IVIG treatment (p=0.000, p=0.003, and p=0.002, respectively). Conclusion: Compared to IVIG replacement, significantly higher and more stable serum IgG levels can be obtained with SCIG replacement. This is expected to ensure improved outcomes in the management of infections in PID patients. https://trendspediatrics.com/article/view/89IgG levelsintravenous immunoglobulin replacementsubcutaneous immunoglobulin replacement |
| spellingShingle | Selime Özen Bölük Nesrin Gülez Canan Karkıner Özgen Soyöz Figen Çelebi Çelik Mehmet Şirin Kaya Idil Akay Hacı Ilke Taşkırdı Ömer Akçal Ferah Genel The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency Trends in Pediatrics IgG levels intravenous immunoglobulin replacement subcutaneous immunoglobulin replacement |
| title | The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency |
| title_full | The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency |
| title_fullStr | The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency |
| title_full_unstemmed | The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency |
| title_short | The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency |
| title_sort | effect of subcutaneous immunoglobulin replacement therapy on serum igg levels in patients with primary immunodeficiency |
| topic | IgG levels intravenous immunoglobulin replacement subcutaneous immunoglobulin replacement |
| url | https://trendspediatrics.com/article/view/89 |
| work_keys_str_mv | AT selimeozenboluk theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT nesringulez theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT canankarkıner theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT ozgensoyoz theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT figencelebicelik theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT mehmetsirinkaya theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT idilakayhacı theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT ilketaskırdı theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT omerakcal theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT ferahgenel theeffectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT selimeozenboluk effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT nesringulez effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT canankarkıner effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT ozgensoyoz effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT figencelebicelik effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT mehmetsirinkaya effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT idilakayhacı effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT ilketaskırdı effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT omerakcal effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency AT ferahgenel effectofsubcutaneousimmunoglobulinreplacementtherapyonserumigglevelsinpatientswithprimaryimmunodeficiency |